Last Updated : June 1, 2021
Details
FilesProject Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
HE0023-000
Osteoporosis is a systemic skeletal disease characterized by a loss of bone mass and an increased risk of fragility fractures. Osteoporosis is highly prevalent, affecting an estimated 1.5 million Canadians over 40 years of age. Fractures associated with osteoporosis commonly occur in vertebral sites, but also occur in non-vertebral sites. They are associated with significant costs, diminished quality of life, and mortality, as well as an increased risk of future fractures.
In Canada, different classes of drugs are indicated for osteoporosis. Of interest to this project are four bisphosphonates (alendronate, risedronate, etidronate, and zoledronic acid), denosumab, and teriparatide. These drugs have been available for decades, are widely used, and have a significant budget impact. This proposed project will evaluate the relative clinical effectiveness and safety of the drugs used in the treatment and prevention of osteoporosis in postmenopausal women.
Files
Last Updated : June 1, 2021